1. Home
  2. NUR vs BIAF Comparison

NUR vs BIAF Comparison

Compare NUR & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuran Wireless Inc. Common Shares

NUR

Nuran Wireless Inc. Common Shares

N/A

Current Price

$0.40

Market Cap

7.8M

Sector

N/A

ML Signal

N/A

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

N/A

Current Price

$2.21

Market Cap

9.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NUR
BIAF
Founded
N/A
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
9.2M
IPO Year
2016
2022

Fundamental Metrics

Financial Performance
Metric
NUR
BIAF
Price
$0.40
$2.21
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 446.6K
88.6K
Earning Date
08-28-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $7,900,000.00
Revenue This Year
N/A
$18.58
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 14.49
52 Week Low
$0.36
$0.37
52 Week High
$7.72
$21.52

Technical Indicators

Market Signals
Indicator
NUR
BIAF
Relative Strength Index (RSI) 25.39 33.29
Support Level $0.36 $1.56
Resistance Level $0.83 $4.35
Average True Range (ATR) 0.09 0.29
MACD 0.00 0.05
Stochastic Oscillator 8.97 1.79

Price Performance

Historical Comparison
NUR
BIAF

About NUR Nuran Wireless Inc. Common Shares

Nuran Wireless Inc is engaged in the Network as a Service (NAAS) business. The group operates in the research, development, manufacturing, marketing, and operation of digital electronic circuits and wireless telecommunication products and offers services in the mobile telephony industry. It also provides products and services that help mobile network operators profitably serve off-grid markets that are currently not served. It has two reportable segments: NaaS and Direct Sales. The majority of the revenue is derived from Africa.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: